Open AccessEmbolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma
Author(s) -
Rossella Rodia,
Stefano Marini,
Filippo Eros Pani,
Francesco Boi,
Stefano Mariotti
Publication year - 2019
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2019-0184
Subject(s) - medicine , lenvatinib , refractory (planetary science) , thyroid carcinoma , metastasis , oncology , embolization , thyroid cancer , radiology , thyroid , surgery , cancer , physics , astrobiology
Lenvatinib is a tyrosine kinase inhibitor (TKI) with antiproliferative and antiangiogenic effects indicated for the treatment of progressive, locally advanced or metastatic progressive thyroid carcinoma, refractory to radioactive iodine therapy. Antiangiogenic therapies induce ischemic necrosis of tumor tissue, with increased risk of hemorrhagic complications. The management of hemorrhagic risk is based on precautionary measures and for any surgical procedure, it is advised to interrupt the treatment in order to avoid complications. ‘Flare-up’ of tumor activity may follow TKI interruption. However, it is not known if continuing TKIs during minimally invasive interventions is safe. We report here the first case in which an embolization of metastasis is performed without interrupting lenvatinib treatment. The procedure was successful and free of complications.